Literature DB >> 18035445

Plasma relaxin concentration is related to beta-cell function and insulin sensitivity in women with type 2 diabetes mellitus.

Barbara Szepietowska1, Maria Gorska, Malgorzata Szelachowska.   

Abstract

We conducted a study to examine an association between relaxin, insulin sensitivity and beta-cell function in women with type 2 diabetes. Relaxin concentration was measured in plasma in 63 newly diagnosed women with type 2 diabetes. We also measured body mass index (BMI), blood pressure, parameters of metabolic control (fasting glucose level, HbA1c, total, HDL and LDL cholesterol, triglycerides) and insulin resistance according to the homeostasis model assessment index 2 (HOMA2). Relaxin was positively related to insulin sensitivity (R=0.316 and p=0.01) and negatively to beta-cell (-0.382 and p=0.004) function. Logistic regression analysis revealed that the correlation between relaxin and HOMA2%B remained significant after adjustment for age, BMI (R(2)=0.253 and p=0.006). Our data raise the possibility that a gender-related hormonal mechanism may influence beta-cell function in women with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18035445     DOI: 10.1016/j.diabres.2007.10.017

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  11 in total

1.  Plasma levels of relaxin-2 are higher and correlated to C-peptide levels in early gestational diabetes mellitus.

Authors:  Yoatzin Alonso Lopez; Jonatan Dereke; Mona Landin-Olsson; Helena Strevens; Charlotta Nilsson; Magnus Hillman
Journal:  Endocrine       Date:  2017-06-29       Impact factor: 3.633

Review 2.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 3.  Glucose control during labor and delivery.

Authors:  Edmond A Ryan; Rany Al-Agha
Journal:  Curr Diab Rep       Date:  2014-01       Impact factor: 4.810

4.  Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes.

Authors:  A Aragón-Herrera; S Feijóo-Bandín; D Rodríguez-Penas; E Roselló-Lletí; M Portolés; M Rivera; M Bigazzi; D Bani; O Gualillo; J R González-Juanatey; F Lago
Journal:  Endocrine       Date:  2018-02-06       Impact factor: 3.633

Review 5.  Secretory products of the corpus luteum and preeclampsia.

Authors:  María M Pereira; Monica Mainigi; Jerome F Strauss
Journal:  Hum Reprod Update       Date:  2021-06-22       Impact factor: 15.610

6.  Association between parity and persistent weight gain at age 40-60 years: a longitudinal prospective cohort study.

Authors:  Bas Van Rijn; Titia Lely; Gerbrand Albertus Zoet; Nina D Paauw; Katrien Groenhof; Arie Franx; Ron T Gansevoort; Henk Groen
Journal:  BMJ Open       Date:  2019-05-05       Impact factor: 2.692

7.  H3 Relaxin Alleviates Migration, Apoptosis and Pyroptosis Through P2X7R-Mediated Nucleotide Binding Oligomerization Domain-Like Receptor Protein 3 Inflammasome Activation in Retinopathy Induced by Hyperglycemia.

Authors:  Kelaier Yang; Jiannan Liu; Xiaohui Zhang; Ziqi Ren; Lei Gao; Ying Wang; Wenjian Lin; Xuefei Ma; Ming Hao; Hongyu Kuang
Journal:  Front Pharmacol       Date:  2020-12-16       Impact factor: 5.810

8.  Carotid Artery Disease in Subjects with Type 2 Diabetes: Risk Factors and Biomarkers.

Authors:  Vadim V Klimontov; Elena A Koroleva; Rustam S Khapaev; Anton I Korbut; Alexander P Lykov
Journal:  J Clin Med       Date:  2021-12-24       Impact factor: 4.241

9.  The effects of physical exercise on plasma levels of relaxin, NTproANP, and NTproBNP in patients with ischemic heart disease.

Authors:  Matthias Heringlake; T Kox; J Poeling; S Klaus; T Hanke; N Franz; F Eberhardt; H Heinze; F P Armbruster; L Bahlmann
Journal:  Eur J Med Res       Date:  2009-03-17       Impact factor: 2.175

Review 10.  Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives.

Authors:  Sandra Feijóo-Bandín; Alana Aragón-Herrera; Diego Rodríguez-Penas; Manuel Portolés; Esther Roselló-Lletí; Miguel Rivera; José R González-Juanatey; Francisca Lago
Journal:  Front Physiol       Date:  2017-08-18       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.